Shenzhen Second People's

Company snapshot

Shenzhen Second People's is a pharma organization headquartered in CN. Primary therapeutic focus areas include Leukemia, Lymphocytic, Acute, B-Cell, Prostate Cancer Indications. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (1), phase 2 (1).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Shenzhen Second People's. Not investment advice.

• What is Shenzhen Second People's?

  Shenzhen Second People's is a pharma organization headquartered in CN. Primary therapeutic focus areas include Leukemia, Lymphocytic, Acute, B-Cell, Prostate Cancer Indications. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity f

• Is Shenzhen Second People's publicly traded?

  Shenzhen Second People's appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Shenzhen Second People's develop or market?

  We link 4 drug profile(s) where Shenzhen Second People's is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/shenzhen-second-people-s-hospital#company-drugs.

• What are the latest developments for Shenzhen Second People's?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Shenzhen Second People's focus on?

  Shenzhen Second People's focuses on Leukemia, Lymphocytic, Acute, B-Cell, Prostate Cancer Indications based on our analysis of their pipeline programs and drug development activities.